{"entity":{"id":"nct03897543","kind":"trial","name":"ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma","aka":[],"tldr":"A phase 1/2 trial of ABX196 in hepatocellular carcinoma, run by Abivax S.A., now recruiting.","summary":"ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT03897543 by Abivax S.A., with 48 participants planned, started 2019-08-30 and due to reach its primary completion in 2021-06-30. Interventions recorded: ABX196.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03897543","url":"https://clinicaltrials.gov/study/NCT03897543"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03897543","phase":"1/2","setting":"A Phase 1-2 Study of ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma","sponsor":"Abivax S.A.","enrolled":48,"outcomes":[]},"route":"/trials/nct03897543/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}]}}